Efficacy of transcatheter arterial infusion chemotherapy for advanced gastric cancer
10.13929/j.issn.1672-8475.2020.04.002
- Author:
Jinhan QIAO
1
Author Information
1. Postgraduate Culture Base, Liaoning Cancer Hospital & Jinzhou Medical College
- Publication Type:Journal Article
- Keywords:
Chemoembolization, therapeutic;
Oxaliplatin;
Stomach neoplasms
- From:
Chinese Journal of Interventional Imaging and Therapy
2020;17(4):198-201
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the curative effect of transcatheter arterial infusion chemotherapy in treatment of advanced gastric cancer (AGC). Methods: Totally 80 AGC patients were randomly divided into observation group and control group (each n=40). Patients in observation group were treated with transcatheter arterial infusion chemotherapy, and those in control group were given SOX regimen. The therapeutic efficacy were compared between groups at the end of 3rd and 6th cycle of chemotherapy, and the adverse reactions were counted. Follow up was performed for 24 months, and progression-free survival time curve was drawn and compared between 2 groups. Results: At the end of 3rd cycle, the effective rate was 69.44% (25/36) of observation group, higher than that of control group (38.46% [15/39], P=0.028). At the end of 6th cycle, the effective rate was 58.82% (20/34) of observation group, 41.67% (15/36) in control group (P=0.511). During 6 cycles of chemotherapy, no significant difference of incidence of side effect was found between 2 groups (P>0.05). After 24 months follow-up, the median progression-free survival was 6.5 months in observation group, 6.0 months in control group (P=0.041). Conclusion: Transcatheter arterial infusion chemotherapy has better short-term curative effect than SOX regimen for treating advanced gastric cancer, which may prolong progression-free survival of patients and be relatively safe.
